England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

A mineralocorticoid receptor antagonist that blocks excess aldosterone and reduces fluid volumes, spironolactone is the ...

Top decision-makers from across the biopharma ecosystem will convene in Chicago for the 2nd BioCentury Grand Rounds – U.S., at the intersection of research, investment and drug development. Designed ...

In this video, Ursula A. Matulonis, MD, discusses results from the phase 3 MIRASOL trial of mirvetuximab soravtansine-gynx for patients with folate receptor alpha-positive, platinum-resistant ovarian ...

In this video, Ursula A. Matulonis, MD, shares that although data from the REFRaME-O1 trial of luveltamab tazevibulin were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer ...

Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...